Story · Medicine & Biotech
Itziar Canamasas: A New Milestone for Boehringer Ingelheim in HER2-Mutant Lung Cancer
1 outlet · first reported by OncoDaily on
Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim, shared Boehringer Ingelheim’s post on LinkedIn, adding: “Precision oncology is not just about finding the right treatment. It is about making (OncoDaily)
Coverage, in order
-
Itziar Canamasas: A New Milestone for Boehringer Ingelheim in HER2-Mutant Lung CancerItziar Canamasas, Global Head of Oncology at Boehringer Ingelheim, shared Boehringer Ingelheim’s post on LinkedIn, adding: “Precision oncology is not just about finding the right treatment. It is about making
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.